Floatz logo

Gefetinib

Bronchoalveolar Cell Lung Cancer

National Cancer Institute (NCI)Phase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bronchoalveolar Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Barbara Ann Karmanos Cancer Institute
Phase 3BB
Docetaxel
Wake Forest University Health Sciences
Phase 3BB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB
PEGFILGRASTIM
Wake Forest University Health Sciences
Phase 2B
Cetuximab
National Cancer Institute (NCI)
Phase 2B
Bortezomib
National Cancer Institute (NCI)
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Gefetinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
71 / 100
View asset →
lung large cell carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →